![Safety and Effectiveness Analysis of Dolutegravir in Patients with HIV-1: Interim Report of Post-Marketing Surveillance in Japan | SpringerLink Safety and Effectiveness Analysis of Dolutegravir in Patients with HIV-1: Interim Report of Post-Marketing Surveillance in Japan | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs12325-021-01842-3/MediaObjects/12325_2021_1842_Fig2a_HTML.png)
Safety and Effectiveness Analysis of Dolutegravir in Patients with HIV-1: Interim Report of Post-Marketing Surveillance in Japan | SpringerLink
![Intranasal vaccination with influenza HA/GO-PEI nanoparticles provides immune protection against homo- and heterologous strains | PNAS Intranasal vaccination with influenza HA/GO-PEI nanoparticles provides immune protection against homo- and heterologous strains | PNAS](https://www.pnas.org/cms/10.1073/pnas.2024998118/asset/ddf2dde8-9010-4b75-82c9-1ce8e7187342/assets/images/large/pnas.2024998118fig03.jpg)
Intranasal vaccination with influenza HA/GO-PEI nanoparticles provides immune protection against homo- and heterologous strains | PNAS
![Diagnostics | Free Full-Text | Dolutegravir Plus Lamivudine Two-Drug Regimen: Safety, Efficacy and Diagnostic Considerations for Its Use in Real-Life Clinical Practice—A Refined Approach in the COVID-19 Era | HTML Diagnostics | Free Full-Text | Dolutegravir Plus Lamivudine Two-Drug Regimen: Safety, Efficacy and Diagnostic Considerations for Its Use in Real-Life Clinical Practice—A Refined Approach in the COVID-19 Era | HTML](https://www.mdpi.com/diagnostics/diagnostics-11-00809/article_deploy/html/images/diagnostics-11-00809-g001.png)
Diagnostics | Free Full-Text | Dolutegravir Plus Lamivudine Two-Drug Regimen: Safety, Efficacy and Diagnostic Considerations for Its Use in Real-Life Clinical Practice—A Refined Approach in the COVID-19 Era | HTML
Short Communication: No Significant Increase in Body Fat Mass in Naive HIV-Infected Patients Starting Raltegravir Plus Tenofovir
![Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial - The Lancet Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2001012425/2003805153/gr1.gif)
Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial - The Lancet
Reduced Number of Transitional and Naive B Cells in Addition to Decreased BAFF Levels in Response to the T Cell Independent Immunogen Pneumovax®23 | PLOS ONE
![Initial steps of the pathogenesis of the infection caused by Streptococcus suis: fighting against nonspecific defenses - Segura - 2016 - FEBS Letters - Wiley Online Library Initial steps of the pathogenesis of the infection caused by Streptococcus suis: fighting against nonspecific defenses - Segura - 2016 - FEBS Letters - Wiley Online Library](https://febs.onlinelibrary.wiley.com/cms/asset/bc1aec27-b561-4ae9-93ce-bf0dc564b380/feb212364-fig-0002-m.jpg)
Initial steps of the pathogenesis of the infection caused by Streptococcus suis: fighting against nonspecific defenses - Segura - 2016 - FEBS Letters - Wiley Online Library
Mucosal immunization with VLP requires adjuvant activity in aged mice... | Download Scientific Diagram
![Th17-polarized effectors protect against lethal flu challenge using... | Download Scientific Diagram Th17-polarized effectors protect against lethal flu challenge using... | Download Scientific Diagram](https://www.researchgate.net/publication/26264663/figure/fig4/AS:667640313966602@1536189263494/Th17-polarized-effectors-protect-against-lethal-flu-challenge-using-novel-mechanisms.png)
Th17-polarized effectors protect against lethal flu challenge using... | Download Scientific Diagram
![Dolutegravir (DTG)-based regimens in HIV-1-infected treatment-naïve... | Download Scientific Diagram Dolutegravir (DTG)-based regimens in HIV-1-infected treatment-naïve... | Download Scientific Diagram](https://www.researchgate.net/publication/335358096/figure/fig1/AS:867989314355201@1583956187633/Dolutegravir-DTG-based-regimens-in-HIV-1-infected-treatment-naive-patients-efficacy-by.png)
Dolutegravir (DTG)-based regimens in HIV-1-infected treatment-naïve... | Download Scientific Diagram
![An atypical lipoteichoic acid from <i>Clostridium perfringens</i> elicits a broadly cross-reactive and protective immune response. - Abstract - Europe PMC An atypical lipoteichoic acid from <i>Clostridium perfringens</i> elicits a broadly cross-reactive and protective immune response. - Abstract - Europe PMC](https://europepmc.org/articles/PMC7363129/bin/SB-JBCJ200080F008.jpg)
An atypical lipoteichoic acid from <i>Clostridium perfringens</i> elicits a broadly cross-reactive and protective immune response. - Abstract - Europe PMC
Reduced Number of Transitional and Naive B Cells in Addition to Decreased BAFF Levels in Response to the T Cell Independent Immunogen Pneumovax®23 | PLOS ONE
![Long-term weight gain after initiating combination antiretroviral therapy in treatment-naïve Asian people living with human immunodeficiency virus - International Journal of Infectious Diseases Long-term weight gain after initiating combination antiretroviral therapy in treatment-naïve Asian people living with human immunodeficiency virus - International Journal of Infectious Diseases](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/f8225e72-36d0-4689-85db-282218602987/gr1.jpg)